ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 139

Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

Mia Glerup1, Ellen D Arnstad 2, Veronika Rypdal 3, Suvi Peltoniemi 4, Kristiina Aalto 5, Marite Rygg 6, Susan Nielsen 7, Anders Fasth 8, Lillemor Berntson 9, Ellen Nordal 3 and Troels Herlin 10, 1Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 2Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, 3Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 4Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, 5Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 6Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, 7Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, 8Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 9Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 10Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Disease Activity, juvenile idiopathic arthritis (JIA), longitudinal studies, Outcome measures, young adults

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission and defined ILAR categories are sustainable further into adulthood remains unknown. The aim of this study was to describe the trajectory of JIA disease course over time by comparing treatment, disease activity and ILAR categories from baseline, 8 and 18 years of disease.

Methods: Included were 510 consecutive cases of JIA with disease onset during 1997-2000 from Denmark, Norway, Sweden and Finland in a longitudinal, population-based 18-year (mean age 17.5 ± 1.7 years) follow-up study. Clinical data was collected consecutively at baseline, 8 and 18 years of disease, and evaluated regarding treatment, disease activity and ILAR category. Descriptive statistics (mean and standard deviation, SD) were used to assess clinical characteristics and chi-squared test to compare categorical data.

Results: Altogether, 434 (85%) were eligible for inclusion by having at least two follow-up visits during the disease course. At the 18-year follow-up 329 (76%) attended a clinical visit, and 105 (24%) completed a standardized telephone interview. Mean age at last follow-up was 24.0 ± 4.4 years (mean ± SD); 68% females. At the 8-year follow-up, 60% were without systemic treatment, which increased significantly to 70% 10 years later at the 18-year follow-up (Risk ratio 1.3; p=0.03) (Table 1).   Out of 178 participants not being in remission at 8-year follow-up, 115 (65%) were still not in remission after 18 years (risk ratio 1.5; p< 0.001) (Table 2). Additionally, out of 151 being in remission off medication 8 years after disease onset, 103 (68%) were still in remission off medication at 18-year follow-up.   The distribution of ILAR categories continued to change throughout the study period (Table 3). In total, 44 patients (10%) changed ILAR category between baseline and 8 years of follow-up. Further, 56 (13%) changed category between the 8 and 18-year follow-up. There was a significant increase in the psoriatic arthritis category from 8 at baseline to 28 at 18-year follow-up (p< 0.001) and a significant decrease in the oligoarticular category (p=0.05) compared to baseline.

Conclusion: In this long-term prospective study in a population-based setting, significantly more patients were off medication after 18-years of follow-up compared to medicines use 8 years after onset, but the number of patients in remission had not increased. The ILAR categories defined after 8 years were not sustainable but changed significantly even beyond 8 years after onset.

Values refer to number (%) of patients; DMARDs: conventional disease_modifying anti_rheumatic drugs; FU: follow_up.

Values refer to number (%) of patients. *According to the preliminary criteria described by Wallace et al. 1 Risk ratio=1.5; p<0.001. 2 Risk ratio=5.8; p<0.001. 3 Risk ratio=1.5; p<0.001.

Values refer to number (%) of patients; FU: follow_up. *Risk ratio and p_values for ILAR category at baseline compared to 18_year follow_up.


Disclosure: M. Glerup, None; E. Arnstad, None; V. Rypdal, None; S. Peltoniemi, None; K. Aalto, None; M. Rygg, None; S. Nielsen, None; A. Fasth, None; L. Berntson, None; E. Nordal, None; T. Herlin, None.

To cite this abstract in AMA style:

Glerup M, Arnstad E, Rypdal V, Peltoniemi S, Aalto K, Rygg M, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T. Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/ongoing-disease-activity-in-juvenile-idiopathic-arthritis-jia-18-years-after-disease-onset-a-population-based-nordic-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ongoing-disease-activity-in-juvenile-idiopathic-arthritis-jia-18-years-after-disease-onset-a-population-based-nordic-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology